NewAmsterdam Pharma Company N.V. Stock-Based Compensation
NewAmsterdam Pharma Company N.V. (NAMS) reported Stock-Based Compensation of $36.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $18.38M, a 21.09% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $18.00M, a 18.33% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $14.02M, a 48.94% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $15.01M, a 87.72% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based payment arrangement, noncash expense for fiscal 2025 was $59.42M, a 76.76% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. share-based payment arrangement, noncash expense for fiscal 2024 was $33.62M, a 36.82% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. share-based payment arrangement, noncash expense for fiscal 2023 was $24.57M, a 496.84% increase from fiscal 2022.
- NewAmsterdam Pharma Company N.V. share-based payment arrangement, noncash expense for fiscal 2022 was $4.12M, a 230.95% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $36.38M 10-Q · filed 2026-08-05 | $50.41M derived: sum of 3 quarters · filed 2026-08-05 | $65.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $18.00M 10-Q · filed 2026-05-07 | $32.02M derived: sum of 2 quarters · filed 2026-05-07 | $47.03M derived: sum of 3 quarters · filed 2026-05-07 | $62.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $14.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $29.03M derived: sum of 2 quarters · filed 2026-02-18 | $44.21M derived: sum of 3 quarters · filed 2026-08-05 | $59.42M 10-K · filed 2026-02-18 |
| 2025-09-30 | $15.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $30.19M derived: sum of 2 quarters · filed 2026-08-05 | $45.40M 10-Q · filed 2025-11-05 | $54.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $15.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $30.39M 10-Q · filed 2026-08-05 | $39.81M derived: sum of 3 quarters · filed 2026-08-05 | $47.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $15.21M 10-Q · filed 2026-05-07 | $24.63M derived: sum of 2 quarters · filed 2026-05-07 | $32.62M derived: sum of 3 quarters · filed 2026-05-07 | $40.91M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $17.41M derived: sum of 2 quarters · filed 2026-02-18 | $25.70M derived: sum of 3 quarters · filed 2026-02-18 | $33.62M 10-K · filed 2026-02-18 |
| 2024-09-30 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $16.29M derived: sum of 2 quarters · filed 2025-11-05 | $24.20M 10-Q · filed 2025-11-05 | $30.21M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | $8.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $16.21M 10-Q · filed 2025-08-06 | $22.21M derived: sum of 3 quarters · filed 2026-02-18 | $27.61M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | $7.92M 10-Q · filed 2025-05-08 | $13.92M derived: sum of 2 quarters · filed 2026-02-18 | $19.32M derived: sum of 3 quarters · filed 2026-02-18 | $24.87M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | $6.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $11.40M derived: sum of 2 quarters · filed 2026-02-18 | $16.96M derived: sum of 3 quarters · filed 2026-02-18 | $24.57M 10-K · filed 2026-02-18 |
| 2023-09-30 | $5.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $10.95M derived: sum of 2 quarters · filed 2024-11-06 | $18.57M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $5.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $13.17M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $7.62M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $4.12M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $1.24M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |